Mixed testicular germ cell cancer

Summary

Mixed testicular germ cell cancer (MONDO:0003120) is a cancer and 3 clinical trials. Top therapeutic interventions include ifosfamide and etoposide phosphate. A subtype of malignant testicular germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mixed testicular germ cell cancer
Mondo ID	MONDO:0003120
DOID	DOID:4743
NCIT	C6347
UMLS	C1336720
MedGen	237005
GARD	0023372
Anatomy (UBERON)	UBERON:0000473
Is cancer (heuristic)	yes

Also known as: mixed germ cell tumor · mixed germ cell tumour · mixed germ cell tumour of testis · mixed germ cell tumour of the testis · mixed testicular germ cell tumour · testicular germ cell tumour (mixed) · testicular mixed germ cell tumour · testis mixed germ cell tumor · testis mixed germ cell tumour

Data availability: 8 cell lines · 10 intOGen driver records.

Disease family

This is a subtype of malignant testicular germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › male reproductive organ cancer › testicular cancer › malignant testicular germ cell tumor › mixed testicular germ cell cancer

Related subtypes (5): testicular non-seminomatous germ cell cancer, testicular seminoma, testis refractory cancer, testis polyembryoma, malignant teratoma of testis

Subtypes (1): childhood testicular mixed germ cell cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT05564026	Not specified	RECRUITING	Molecular Epidemiology of Pediatric Germ Cell Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IFOSFAMIDE	4	2
ETOPOSIDE PHOSPHATE	4	1